Insights › Market reaction

Why Savara (SVRA) Stock Fell 20.55% in 10 Minutes on Nov 20, 2026

The 20.55% drop was larger than any reaction MoveSurge measured after Savara headlines between Aug 22, 2026 and Nov 19, 2026; the largest of those was -0.21% in 10 minutes, on Oct 21, 2026.

Published in ET: Feed time in ET: Regulation SVRA -20.55% in 10 min after the headline
  • SVRA fell 20.55% in the 10 minutes after the 08:30:39 ET headline, from $5.25 to $4.17.
  • 495,111 shares changed hands in those 10 minutes.
  • The headline crossed in pre-market trading, 1 hour before the 9:30 ET open.
SVRA Why Savara (SVRA) Stock Fell 20.55% in 10 Minutes on Nov 20, 2026
MoveSurge publish 08:30:39 ET
MoveSurge publish
08:30:39 ET
5.42 4.60 3.75 2.93 4.17 08:28 08:30 08:40
Real 1-minute OHLC candles around publish time. Chart times are New York ET; validated market data captured by MoveSurge.

Reaction by asset (real prices)

Asset2m beforeAt release+1m+10m+1m %+10m %
SVRA 5.25 5.25 4.00 4.17 -23.79% -20.55%

Savara (SVRA) shares fell 20.55% in the 10 minutes after this headline reached the MoveSurge news feed at 08:30:39 ET on Friday, November 20, 2026: “FDA will miss its Nov. 22, 2026 target date for Savara’s molgramostim inhalation solution application; review continues with no new date set”

SVRA in the first 10 minutes

From a reference price of $5.25 just before the headline, the stock was down 23.79% after one minute and down 20.55%, at $4.17, after 10 minutes. Part of the first-minute move came back by the 10-minute mark. 495,111 shares changed hands in those 10 minutes. The headline crossed in pre-market trading, 1 hour before the 9:30 ET open.

Earlier SVRA headlines and the measured reaction

The 20.55% drop was larger than any reaction MoveSurge measured after Savara headlines between Aug 22, 2026 and Nov 19, 2026; the largest of those was -0.21% in 10 minutes, on Oct 21, 2026.

  1. Oct 21, 2026, 13:10 ET: “Savara reports improved pulmonary gas transfer with daily molgramostim in post-hoc analysis of Phase 2/3 IMPALA trial patients with mild diffusion impairment” (-0.21% in 10 minutes)

Savara at a glance

SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
Market value$1.15 billion (as of Nov 20, 2026)

Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.

What headline moved Savara stock on November 20, 2026?

At 08:30:39 ET, this headline crossed: “FDA will miss its Nov. 22, 2026 target date for Savara’s molgramostim inhalation solution application; review continues with no new date set”. The stock fell 20.55% in the next 10 minutes.

How far did SVRA move after the headline?

From $5.25 just before the headline to $4.17 10 minutes later, a -20.55% move.

Sources

Follow SVRA live

The live feed pairs breaking headlines with measured price moves. Build a watchlist of stocks you own and choose whether matching news reaches your WhatsApp.

Open the live feed See portfolio WhatsApp alerts
The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Core market coverageEquities, macro, currencies and commodities Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources
Go real time View the live feed Subscription renews automatically. Cancel before renewal. Information only—no trade calls.